Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis-Reference-Cited by-同舟云学术

Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis

Published:2014-06-13 Issue:9 Volume:14 Page:1063-1073
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Abdel-Rahman Omar,Fouad Mona

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

http://www.tandfonline.com/doi/pdf/10.1586/14737140.2014.929501

Reference87 articles.

1. Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside

2. Sunitinib for the treatment of metastatic renal cell carcinoma

3. Benefit-Risk Assessment of Sunitinib in Gastrointestinal Stromal Tumours and Renal Cancer

4. Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endocrine Complications of the Hematologic Disorders and of Their Treatment;Reference Module in Biomedical Sciences;2024

2. Aneurysm and Artery Dissection After Oral VEGFR-TKI Use in Adults With Cancer;JAMA Network Open;2023-11-29

3. Prior Anti-Angiogenic TKI-Based Treatment as Potential Predisposing Factor to Nivolumab-Mediated Recurrent Thyroid Disorder Adverse Events in mRCC Patients: A Case Series;Biomedicines;2023-11-04

4. Endocrinopathies from checkpoint inhibitors: Incidence, outcomes, and management;Cleveland Clinic Journal of Medicine;2023-05

5. Endocrine-related adverse conditions induced by tyrosine kinase inhibitors;Annales d'Endocrinologie;2023-05